Last reviewed · How we verify
Fluticasone Propionate Nasal Spray, 50 mcg
At a glance
| Generic name | Fluticasone Propionate Nasal Spray, 50 mcg |
|---|---|
| Sponsor | Alcon Research |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD) (PHASE2)
- Efficacy and Safety of On-demand and Continuous Administration of Nasal Spray in the Treatment of Allergic Rhinitis (PHASE4)
- Bioequivalence Study of Azelastine Hydrochloride/ Fluticasone Propionate 137 Microgram/50 Microgram Nasal Spray and Dymista Nasal Spray (PHASE1)
- Allergic Rhinitis Combination Pharmacotherapy Efficacy Study (PHASE4)
- A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergic Rhinitis (PHASE2)
- Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients (PHASE3)
- Impact Of Montelukast On Allergic Rhinitis And Its Inflammatory Makers (EARLY_PHASE1)
- Role of Montelukast in the Management of Chronic Rhinosinusitis With Nasal Polyps. (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluticasone Propionate Nasal Spray, 50 mcg CI brief — competitive landscape report
- Fluticasone Propionate Nasal Spray, 50 mcg updates RSS · CI watch RSS
- Alcon Research portfolio CI